ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / TECH / earnings
TWST (52) RGEN (64) QGEN (71) KYMR (50) ⌘ Pro Terminal →

Bio-Techne Corp (TECH) Next Earnings Date & Expected ±1.8% Move

$72.66 -0.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $72.83

Bio-Techne Corp (TECH) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (65% profit margin, 3% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate) →
ROARABLE B • BUY Cap $11.40B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TECH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TECH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Bio-Techne Corp (NASDAQ: TECH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $72.66 (-0.07% 1D, market cap $11.40B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, TECH ranks #65 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TECH compare to TWST and RGEN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TECH carries a Roarable B (72/100 RQD), trailing P/E of 155.3x, gross margin of 64.8%, and ROIC of 3.4%. By comparison, TWST (Twist Bioscience Corporation) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -11.7%, cap $11.50B) and RGEN (Repligen Corporation) posts a C grade (64/100 RQD, P/E N/A, ROIC 2.3%, cap $10.69B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while QGEN leads on capital efficiency (8.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TECH?
▼

Per TECH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000842023), Bio-Techne Corp generated $1.22B in revenue (+5.2% YoY), $73.4M in net income, and $256.6M in free cash flow against $2.52B in total assets and $590.3M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $72.83 (+0.23%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 21% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510072
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B+
Cash (14)Whales (17)SEC (18)Macro (14)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE+6.3% Base Target
$91 Bull$77 Base$60 Bear
📬 FREE TECH RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TECH)Realized 20D OHLCV Swing Band: ±1.8%
Deterministic 5-Pillar Attribution (72/100 Composite)
🔍 WHY TECH SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)

Altman Z-Score 7.12 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Whale & Options Positioning+17/20 pts (24% of score)

20D Institutional Volume Accumulation (±1.8% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
64
Grade C+$72.48+0.1% Next Q
Q2 (-2Q)
67
Grade B-$72.58+0% Next Q
Q3 (-1Q)
69
Grade B-$72.60+0.1% Next Q
Current
72
Grade B$72.66+7% Hist 90D α
Trajectory: C+ (64) → B (72)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the TECH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 72/100 (B) score, TECH faces multiple-compression risk if 155.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Priced at 155x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($72.47) or 200D SMA ($63.19) invalidates the momentum regime and cuts Target Base ($77.24) toward Bear Floor ($59.58).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TECH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TECH Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 72%NO 28%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 28, 2026 (~55 DAYS)

Historical OHLCV Volatility ±1.8% Swing Band

±$1.31 Expected Swing
$71.35 (-1.8%)Spot $72.66$73.97 (+1.8%)
MODEL EARNINGS SETUP GAUGE

TECH Quantitative Pre-Earnings Setup: 72/100

Trailing EPS: $0.47 • YoY Revenue Growth: 5.2%

Model Bullish Setup (72/100)Model Risk Weight (28/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-06-30$1.22B$73.4M$256.6M64.8%
FY 20242024-06-30$1.16B$168.1M$236.1M66.4%
FY 20232023-06-30$1.14B$285.3M$203.2M64.8%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating TECH & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on TECH
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TECH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +32.74%⚡ TESTING RESISTANCE
2026-11-02O $72.69H $72.71L $72.66C $72.66VOL 2.89M
RES: $72.79SMA50: $72.47SMA200: $63.19
$74.82$66.25$57.68$49.11$40.54RES $72.79$72.662026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TECH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TECH Butterfly Map → + Track TECH →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
48.0%/yr Implied 5Y Growth

vs. +5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TECH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TECH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TECH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TECH)

Health Care Rank #65 of 1016 ⚔️ TWST vs TECH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TECH vs. TWST, RGEN, QGEN, KYMR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bio-Techne Corp (TECH) ranks #65 by composite RQD confidence (72/100, grade B) and #98 by equity capitalization ($11.40B). Within this direct 5-issuer industry benchmark cohort, QGEN leads on earnings valuation at 24.4x trailing P/E, while QGEN leads on capital efficiency and profitability with 8.0% ROIC and 62.2% gross margin. TECH currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TECH ACTIVE
Bio-Techne Corp
B 72/100 155.3x 64.8% 3.4% -0.07% $11.40B Benchmark Subject
TWST
Twist Bioscience Corporation
D+ 52/100 — 94.2% -11.7% -11.92% $11.50B /twst-vs-tech →
RGEN
Repligen Corporation
C 64/100 — 88.2% 2.3% -6.20% $10.69B /rgen-vs-tech →
QGEN
Qiagen N.V.
B- 71/100 24.4x 62.2% 8.0% -0.24% $10.37B /qgen-vs-tech →
KYMR
Kymera Therapeutics Inc.
D 50/100 32.7x — -21.4% +3.29% $10.19B /kymr-vs-tech →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000842023

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Bio-Techne Corp (TECH) reported GAAP revenue of $1.22B (+5.2% vs. FY2024 revenue of $1.16B , and +7.3% cumulative change since FY2023) , GAAP net income of $73.4M, operating cash flow of $287.6M, and free cash flow of $256.6M (+8.7% YoY). On the balance sheet, TECH closed FY2025 with $2.52B in total assets against $590.3M in total debt (Altman Z-Score: 7.12, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $1.22B $73.4M $287.6M $256.6M $2.52B $590.3M
FY2024 (FY) 2024-06-30 $1.16B $168.1M $299.0M $236.1M $2.67B $624.9M
FY2023 (FY) 2023-06-30 $1.14B $285.3M $254.4M $203.2M $6.27B $1.47B

3. TECH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TECH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Bio-Techne Corp (NASDAQ: TECH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $72.66 (-0.07% 1D, market cap $11.40B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, TECH ranks #65 in composite RQD confidence.

How does TECH compare to TWST and RGEN in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TECH carries a Roarable B (72/100 RQD), trailing P/E of 155.3x, gross margin of 64.8%, and ROIC of 3.4%. By comparison, TWST (Twist Bioscience Corporation) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -11.7%, cap $11.50B) and RGEN (Repligen Corporation) posts a C grade (64/100 RQD, P/E N/A, ROIC 2.3%, cap $10.69B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while QGEN leads on capital efficiency (8.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TECH?

Per TECH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000842023), Bio-Techne Corp generated $1.22B in revenue (+5.2% YoY), $73.4M in net income, and $256.6M in free cash flow against $2.52B in total assets and $590.3M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TECH trading relative to its 50-day, 200-day, and 52-week technical levels?

TECH last traded at $72.66 (-0.07% on volume of 2,565,964 shares), positioning the stock +0.26% above its 50-day simple moving average ($72.47) and +14.99% above its 200-day simple moving average ($63.19). Across its 52-week range of $43.20 to $72.75, TECH sits at the 99.7% percentile with a 14-day RSI of 59.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±1.8% ($71.35 to $73.97).

TECH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is TECH's next earnings date?

Based on SEC filing cadence, Bio-Techne Corp (TECH)'s next quarterly reporting window is estimated around Dec 28, 2026.

How much is TECH stock expected to move on earnings?

Volatility modeling currently projects a ±1.8% event move for TECH, spanning a range between $71.35 and $73.97.

Direct Sub-Reports: TECH RQD Cockpit TECH 12M Forecast TECH Earnings & Move TECH Dividends & DRIP TECH Insiders & 13F TECH Whale Options TECH Profit Sankey TECH News & Why
ROARABLE RATING BRIEF • RQD 72/100 (B) ✓ STAGE-C NUMBER FIREWALL VERIFIED

TECH — Bio-Techne Corp: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:15:54Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, TECH scores 72 out of 100 (letter grade B, verdict "Roarable Buy — Good Risk/Reward"). The five pillars are:

  • Fundamental Cash Engine: 14 / 20 — ROIC of 3.4% and FCF yield of 2.25%. Returns on invested capital are modest relative to the stock's multiples, which means the cash generation case is present but not strong on a yield basis.
  • Whale 13F Flow: 17 / 20 — Institutional accumulation and options positioning are the highest-scoring pillar, indicating the strongest support signal in the rating. Holder detail itself is not available in source data.
  • Insider Conviction: 9 / 20 — The lowest pillar, reflecting weaker SEC Form 4 and Congressional PTR cluster flow. For a prospective investor, this is the least-supported part of the thesis.
  • Macro Regime Fit: 14 / 20 — Beta of 0.88 indicates below-market sensitivity to broad moves, with sector sensitivity noted in the rating.
  • Forensic Balance Sheet: 18 / 20 — Altman Z of 7.12, Piotroski F of 8/9, and Debt/Equity of 0.25 make this the strongest pillar and the main defensive argument.

Investor implications: the rating reflects a balance-sheet-strong, institutionally-supported profile paired with rich valuation (P/E TTM of 155.3, EV/EBITDA of 91.3) and thin cash returns (ROIC 3.4%). Upside depends on earnings growth catching up to the multiples; the valuation tradeoff is the central risk. This is an analytical summary, not personalized advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
72.71$11.4B155.314091.30.470.44%0.88$43.2 - $72.753.4%

Business

Bio-Techne Corp (TECH) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company has a market capitalization of $11.4B. Products, customer base, and revenue model details are not available in source data.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$1219.6M$102.3M$73.4MN/A$256.6M$172.9M$590.3M
FY 2024$1159.1M$206.7M$168.1MN/A$236.1M$177.5M$624.9M
FY 2023$1136.7M$298.9M$285.3MN/A$203.2MN/A$1467.5M

Per the SEC financials, revenue rose from $1136.7M (FY 2023) to $1219.6M (FY 2025), while operating and net income declined over the same span. Per the market data, gross margin is 64.8%, operating margin 8.4%, and net margin 6%. Per the Roarable RQD rating, the Altman Z-Score is 7.12 and the Piotroski F-Score is 8/9. Debt/Equity is 0.25 and reported debt fell from $1467.5M to $590.3M across the periods shown.

Open Questions

  • What drives revenue growth given the decline in operating and net income from FY 2023 to FY 2025?
  • What explains the gap between the 155.3 P/E (TTM) and the 0.47 EPS, and what is the earnings trajectory implied by the 140 forward P/E?
  • Which institutional holders account for the Whale 13F Flow score, and what is the size and direction of their positions?
  • What are the specific Q1 earnings date, expectations, and guidance referenced in the news wire?
  • Why are EPS values for all reported periods listed as N/A, and what is the cash balance for FY 2023?

TECH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Bio-Techne Corp (TECH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TECH Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TECH Bull vs. Bear Conversation Board — What's Your Call at $72.66?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TECH 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TECH:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $85.80 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is TECH (B • RQD 72/100) a Buy at $72.71?

Welcome to the TECH (Bio-Techne Corp) Roar Pit. Current RQD Composite is 72/100 (Roarable Buy — Good Risk/Reward) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (155.3x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $57.44 (-21.0%)
Spot @ $72.71

Pump the brakes on TECH — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on TECH, but look at what you are paying: 155.3x trailing P/E with 64.8% gross margins. Unless Bio-Techne Corp expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $82.89 (+14.0%)
Spot @ $72.71

TECH cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on TECH, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $72.71 (52-wk range $43.20 - $72.75), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%